for people ages 18-75 (full criteria)
study started
estimated completion



This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).

Official Title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction


Heart Failure Reduced Ejection Fraction INL1 INL1 50mg BID INL1 150 mg BID INL1 300 mg BID


You can join if…

Open to people ages 18-75

  • Clinical diagnosis of HF requiring chronic treatment of loop diuretics
  • Left Ventricular Ejection Fraction (LVEF) ≤ 40% at screening by echocardiography
  • N-Terminal-prohormone of Brain Natriuretic Peptide (NT-proBNP) ≥400 pg/mL at screening for patients without atrial fibrillation or atrial flutter, or, NT-proBNP ≥ 1,200 pg/mL at screening for patients with atrial fibrillation or atrial flutter
  • Treated for Heart Failure with stable, optimal pharmacological therapy
  • Acceptable screening echocardiographic image quality

You CAN'T join if...

  • Female patients of childbearing potential
  • Patients with a New York Heart Association (NYHA) Class I or IV
  • Heart failure that is clearly caused by toxin / drug such as Adriamycin
  • Significant medical conditions or recent history suggesting the patient's study participation will potentially pose a major risk to patient's safety and well-being
  • Need for routine scheduled outpatient IV infusions for Heart Failure or scheduled ultrafiltration
  • History of rhabdomyolysis or history of autoimmune diseases
  • Severe renal disease
  • Hepatic disease
  • Pulmonary disease limiting exercise capacity
  • Atrial fibrillation with rapid ventricular response
  • Life expectancy of less than 6 months
  • Type 1 diabetes mellitus or Type 2 diabetes mellitus with very poor glycemic control
  • Patients with anemia


  • UCLA School of Medicine accepting new patients
    Torrance California 90502 United States
  • Via Christi Research, a division of Via Christi Hospitals Wichita, Inc. accepting new patients
    Wichita Kansas 67214 United States


accepting new patients
Start Date
Completion Date
Innolife Co., Ltd.
Phase 2
Study Type
Last Updated